Circulating hapln1 protein for determining multiple myeloma prognosis, diagnosis, and treatment

Detecting HAPLN1 protein levels in peripheral blood samples offers a non-invasive and cost-effective method for multiple myeloma prognosis and treatment, addressing the limitations of invasive bone marrow analyses.

WO2026236257A1PCT designated stage Publication Date: 2026-11-12WISCONSIN ALUMNI RES FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026739
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current methods for diagnosing and stratifying multiple myeloma require complex genomic analyses of bone marrow samples, which are invasive and costly, and there is a need for non-invasive methods to determine prognosis and treatment.

Method used

Detecting levels of HAPLN1 protein in peripheral blood samples and comparing them to a baseline to determine multiple myeloma prognosis and treatment, using immunoassays to quantify HAPLN1 protein levels.

Benefits of technology

Provides a non-invasive, cost-effective method for determining multiple myeloma prognosis and treatment by analyzing HAPLN1 protein levels in peripheral blood samples, enabling accurate prognosis and treatment decisions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026739_12112026_PF_FP_ABST
    Figure US2026026739_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are methods of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma. Also described herein are methods of determining treatment for a subject having multiple myeloma. The methods may comprise detecting a level of HAPLN1 protein in a peripheral blood sample.
Need to check novelty before this filing date? Find Prior Art

Description

Atty Docket Nos. P250229W001 | 218707-0027-W001CIRCULATING HAPLN1 PROTEIN FOR DETERMINING MULTIPLE MYELOMA PROGNOSIS, DIAGNOSIS, AND TREATMENTCROSS-REFERENCE TO RELATED APPLICATION(S)

[0001] This application claims priority to U. S. Provisional Patent Application No. 63 / 803,072, filed on May 9, 2025, the entire contents of which are incorporated herein by reference.STATEMENT OF GOVERNMENT INTEREST

[0002] This invention was made with government support under grant number CA251595 awarded by the National Institutes of Health. The government has certain rights in the invention.REFERENCE TO SEQUENCE LISTING

[0003] This application was filed with a Sequence Listing XML in ST.26 XML format in accordance with 37 C. F. R. § 1.821 and PCT Rule 13ter. The Sequence Listing XML file submitted in the USPTO Patent Center, “218707-0027-W001_Sequence Listing.xml,” was created on May 4, 2026, contains 13 sequences, has a file size of 16 Kbytes (16,384 bytes), and is incorporated by reference in its entirety into the specification.TECHNICAL FIELD

[0004] The present disclosure relates to methods of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma. The present disclosure also relates to methods of determining treatment for a subject having multiple myeloma. The disclosed methods may comprise detecting a level of HAPLN1 protein in a peripheral blood sample from a subject.INTRODUCTION

[0005] Multiple myeloma is a plasma B-cell malignancy frequently detected in multiple bone marrow sites in patients where cancer cells are dependent on the bone marrow microenvironment for their survival and proliferation. Current standard diagnosis and disease stratification for multiple myeloma requires complex genomic analyses of cancer cells obtained from bone marrow aspiration, which is a painful and expensive procedure.Atty Docket Nos. P250229W001 | 218707-0027-W001SUMMARY

[0006] In one aspect, a method of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma is disclosed. The method may comprise collecting a peripheral blood sample from the subject; detecting a level of HAPLN1 protein in the peripheral blood sample; comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample; and when the level of HAPLN 1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample: determining a first multiple myeloma prognosis for the subject related to subject outcome, determining a second multiple myeloma prognosis for the subject related to treatment response, determining the subject as having multiple myeloma, or combinations thereof.

[0007] In another aspect, a method of determining treatment for a subject having multiple myeloma is disclosed. The method may comprise collecting a peripheral blood sample from the subject; detecting a level of HAPLN1 protein in the peripheral blood sample; comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample; and determining an appropriate multiple myeloma treatment for the subject based on the level of the HAPLN1 protein in the peripheral blood sample relative to the baseline level of HAPLN 1 protein in the control sample; wherein when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN 1 protein in the control sample, the subject is administered a therapeutically effective amount of a non-standard multiple myeloma treatment; or wherein when the level of HAPLN1 protein in the peripheral blood sample is not greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a standard multiple myeloma treatment.

[0008] This disclosure provides other aspects and embodiments that will be apparent in light of the following detailed description and accompanying figure.BRIEF DESCRIPTION OF THE DRAWINGS

[0009] The Figure is a graph showing a standard curve of recombinant HAPLN1 protein concentration used in an AlphaLISA® immunoassay (Revvity, Inc.) to determine HAPLN 1 protein levels in samples from a multiple myeloma patient.Atty Docket Nos. P250229W001 | 218707-0027-W001DETAILED DESCRIPTION

[0010] Disclosed herein are methods of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma. Also disclosed herein are methods of determining treatment for a subject having multiple myeloma. The disclosed methods may comprise detecting a level of HAPLN1 protein in a peripheral blood sample from a subject and comparing the detected HAPLN1 protein level to a baseline level of HAPLN1 protein in a control sample.

[0011] In one aspect, when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, a first multiple myeloma prognosis related to subject outcome is determined for the subject, a second multiple myeloma prognosis related to treatment response is determined for the subject, and / or the subject is determined as having multiple myeloma.

[0012] In another aspect, when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a non-standard multiple myeloma treatment; or, when the level of HAPLN1 protein in the peripheral blood sample is not greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a standard multiple myeloma treatment.

[0013] In various aspects, the methods disclosed herein provide a peripheral blood-based clinical test for multiple myeloma prognosis, diagnosis, and / or treatment.I. Definitions

[0014] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein may be used in practice or testing of the present disclosure. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

[0015] The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or wordsAtty Docket Nos. P250229W001 | 218707-0027-W001that do not preclude the possibility of additional acts or structures. The singular forms “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of’ and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.

[0016] The modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (for example, it includes at least the degree of error associated with the measurement of the particular quantity). The modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression “from about 2 to about 4” also discloses the range “from 2 to 4.” The term “about” may refer to plus or minus 10% of the indicated number. For example, “about 10%” may indicate a range of 9% to 11%, and “about 1” may mean from 0.9- 1.1. Other meanings of “about” may be apparent from the context, such as rounding off, so, for example “about 1” may also mean from 0.5 to 1.4.

[0017] For the recitation of numeric ranges herein, each intervening number therebetween with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

[0018] The term “amino acid” as used herein refers to naturally occurring and non-natural synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code. Amino acids can be referred to herein by either their commonly known three-letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Amino acids include the side chain and polypeptide backbone portions.

[0019] The terms “peptide” and “polypeptide” as used herein refer to a linked sequence of two or more amino acids linked by peptide bonds. The polypeptide can be natural, synthetic, or a modification or combination of natural and synthetic. Peptides and polypeptides may include proteins such as binding proteins, receptors, and antibodies. The terms “polypeptide,” “protein,” and “peptide” may be used herein interchangeably. “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. Certain structures within proteins are commonly referred to asAtty Docket Nos. P250229W001 | 218707-0027-W001domains, for example, enzymatic domains, extracellular domains, transmembrane domains, signaling domains, and binding domains. “Domains” are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Exemplary domains include domains with enzymatic activity or ligand binding activity. “Functional domain” as used herein refers to a portion of a polypeptide that has the ability to promote a particular biological response or process, or contributes to the overall function of the polypeptide (e.g., binding to other molecules or activating signaling pathways). Typical domains are made up of sections of lesser organization such as stretches of beta-sheet and alpha-helices. “Tertiary structure” refers to the complete three-dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three-dimensional structure formed by the noncovalent association of independent tertiary units. A “motif’ is a portion of a polypeptide sequence and includes at least two amino acids. A motif may be 2 to 20, 2 to 15, or 2 to 10 amino acids in length. A motif may include 3, 4, 5, 6, or 7 sequential amino acids. A domain may be comprised of a series of the same type of motif.

[0020] The term “variant” as used herein refers to a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but that retains at least one biological activity. Variant may also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. Representative examples of “biological activity” include the ability to be bound by a specific antibody or polypeptide or to promote a particular biological response or process. Variant can also mean a functional fragment thereof. Variant can also mean multiple copies of a polypeptide that can be in tandem or separated by a linker. A conservative substitution of an amino acid, for example, replacing an amino acid with a different amino acid of similar properties (for example, hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes may be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes may be substituted and still retain protein function. The hydrophilicity of amino acids may also be used to reveal substitutions that would result in proteins retaining biological function. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatibleAtty Docket Nos. P250229W001 | 218707-0027-W001with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.

[0021] The term “matrikine” as used herein refers to a neofunctional peptide fragment derived from an extracellular matrix (ECM) protein, such as HAPLN1. Matrikines are produced from partial cleavage or proteolysis of ECM proteins by proteolytic enzymes including matrix metalloproteinases (e.g., matrix metalloproteinase 2 (MMP-2)). These matrikines are bioactive peptide fragments that can interact with cell surface receptors to regulate and promote specific cellular processes. Matrikines described herein exhibit biological activity as they can be bound by a specific antibody or polypeptide and promote a particular biological response or process.

[0022] As used herein, “homology” or “identical,” percent “identity” or “similarity,” when used in the context of two or more polypeptide sequences, refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues that are the same, e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher sequence identity over a specified region (e.g., amino acid sequence of a HAPLN1 protein described herein). Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. The alignment and the percent homology or sequence identity can be determined using methods and software programs known in the art. For example, one alignment program is BLASTP, using default parameters. The terms “homology,” “identical,” percent “identity,” or “similarity” also refer to, or can be applied to, the complement of a test sequence. The terms also include sequences that have deletions and / or additions, as well as those that have substitutions. An “unrelated” or “non-homologous” sequence shares less than 40% identity, or alternatively less than 25% identity, with one of the sequences of the present disclosure.

[0023] The term “antibody” as used herein collectively refers to immunoglobulins or immunoglobulin-like molecules including by way of example and without limitation, IgA, IgD, IgE, IgG and IgM, combinations thereof, and similar molecules produced during an immune response in any vertebrate, for example, in mammals such as humans, goats, rabbits and mice, as well as non-mammalian species. As used herein, the term “antibody” is used in the broadest senseAtty Docket Nos. P250229W001 | 218707-0027-W001and specifically encompasses monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity. The term “antibody” includes intact immunoglobulins and “antibody fragments” or “antigen binding fragments” that specifically bind to a molecule of interest (or a group of highly similar molecules of interest) to the substantial exclusion of binding to other molecules (for example, antibodies and antibody fragments that have a binding constant for the molecule of interest that is at least 103M-1greater, at least 104M-1greater, or at least 105M-1greater than a binding constant for other molecules in a biological sample). One characteristic that influences the specificity of an antibody: antigen interaction is the affinity of the antibody for the antigen. Although a desired specificity may be reached with a range of different affinities, generally preferred antibodies will have an affinity (a dissociation constant) of about 10-6, 10-7, 10-8, 10-9or less.

[0024] The term “antibody” also includes genetically engineered forms such as recombinant antibodies and chimeric antibodies (for example, humanized murine antibodies), and heteroconjugate antibodies (such as, bispecific antibodies). See also, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, Ill.); Kuby, J., Immunology, 3rd Ed., W. H. Freeman & Co., New York, 1997. More particularly, “antibody” refers to a polypeptide ligand comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen. Antibodies are composed of a heavy (H) and a light (L) chain, each of which has a variable region, termed the variable heavy (VH) region and the variable light (VL) region. Together, the VH region and the VL region are responsible for binding the antigen recognized by the antibody. Typically, an immunoglobulin has heavy (H) chains and light (L) chains interconnected by disulfide bonds. There are two types of light chain, lambda (1) and kappa (K). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each heavy and light chain contains a constant region and a variable region, (the regions are also known as “domains”). In combination, the heavy and the light chain variable regions specifically bind the antigen. Light and heavy chain variable regions contain a “framework” region interrupted by three hypervariable regions, also called “complementarity-determining regions” or “CDRs.” The CDRs are primarily responsible for binding to an epitope of an antigen. Antibodies with different specificities (i.e., different combining sites for different antigens) have different CDRs. Although it is the CDRs that varyAtty Docket Nos. P250229W001 | 218707-0027-W001from antibody to antibody, only a limited number of amino acid positions within the CDRs are directly involved in antigen binding. These positions within the CDRs are called specificity determining residues (SDRs). As disclosed herein, an antibody that binds a HAPLN protein will have a specific VH region and the VL region sequence, and thus specific CDR sequences that recognize an epitope of a HAPLN1 protein antigen.

[0025] The term “monoclonal antibody” or “monoclonal antibodies” as used herein refers to an antibody or population of antibodies typically produced by a single clone of B-lymphocytes or by a cell into which the light and heavy chain genes of a single antibody have been transfected. Monoclonal antibodies are produced by methods known to those of skill in the art, for instance by making hybrid antibody-forming cells from a fusion of myeloma cells with immune spleen cells (i.e., “hybridomas”). Monoclonal antibodies include humanized monoclonal antibodies. Monoclonal antibodies are highly specific, being directed against a single antigenic site (i.e., the same epitope). Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively between the desired antigens and cross-reacting polypeptides.

[0026] The term “polyclonal antibody” or “polyclonal antibodies” as used herein refers to a heterogeneous mixture or population of antibodies that recognize various antigenic sites (i.e., different epitopes) on a single antigen. Polyclonal antibodies are typically produced by multiple B-cell clones in response to an antigen.

[0027] The term “assay” or “diagnostic assay” or “prognostic assay” as used herein can refer to any type of clinically relevant assay applied in the field of diagnostics and prognostics. In some instances, such an assay may be based on the binding of an analyte or biomarker to be detected to one or more capture probes (e.g., antibodies) with a certain affinity. For example, the assay may be an immunoassay. Non-limiting examples of an immunoassay include an ELISA assay, a competitive or inhibition ELISA assay, a sandwich ELISA assay, an ELISA microarray, an amplified luminescent proximity homogenous assay-linked immunosorbent assay, a bioluminescence assay, a fluorescence resonance energy transfer (FRET) immunoassay, a lateral flow immunoassay, or combinations thereof. In some instances, a diagnostic assay may include other clinically relevant techniques and platforms such as, for example, mass spectrometry and / or microarray analysis that are known in the art.Atty Docket Nos. P250229W001 | 218707-0027-W001

[0028] The term “biomarker” as used herein refers to an indicator, e.g., predictive, diagnostic, and / or prognostic, which can be detected in a sample. The biomarker may serve as an indicator of a particular subtype of a disease or disorder (e.g., multiple myeloma) characterized by certain, molecular, pathological, histological, and / or clinical features. When performing an assay described herein, a biomarker can also be referred to as an “analyte” or “target analyte.”

[0029] The terms “detecting” and “detection” are used herein in the broadest sense to include both qualitative and quantitative measurements of a target molecule (e.g., HAPLN1 protein). Detecting includes identifying the mere presence of the target molecule in a sample as well as determining whether the target molecule is present in the sample at detectable levels. Detecting may be direct or indirect.

[0030] The term “multiple myeloma” or “MM” as used herein refers to a clinically diagnosed B-cell cancer malignancy of mature plasma cell morphology characterized by the neoplastic transformation of a single clone of these types of plasma cells. These plasma cells proliferate in bone marrow and may invade adjacent bone and sometimes the blood. Variant forms of multiple myeloma and related pre-cancerous conditions may include overt multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, plasma cell leukemia, non-secretory myeloma, IgD myeloma, osteosclerotic myeloma, solitary plasmacytoma of bone, and extramedullary plasmacytoma. Newly diagnosed multiple myeloma patients (i.e., diagnosed within 6 months to 1 year) typically range in average age from about 60 years old to about 70 years old. Multiple myeloma can also refer to relap sed / refractory multiple myeloma (RRMM). Relapsed refractory multiple myeloma is a later stage of multiple myeloma where the disease has returned (i.e., relapsed) after an initial response to a treatment, and the multiple myeloma cancer cells have become resistant to further treatment.

[0031] The terms “patient” and “subject” as used herein are used interchangeably and mean a mammal. Example mammals include humans, mice, rats, guinea pigs, dogs, cats, horses, cows, pigs, or non-human primates, such as chimpanzees, baboons, or rhesus. The subject may be of any age or stage of development, such as, for example, an adult, an adolescent, or an infant. In some instances, the subject may be at least 40 years old, at least 45 years old, at least 50 years old, at least 55 years old, at least 60 years old, at least 65 years old, or at least 70 years old. The subject may be male or female. The subject may be undergoing treatment either for a disease or condition being diagnosed or for another disease or condition, or other forms of treatment. In some instances,Atty Docket Nos. P250229W001 | 218707-0027-W001described herein, a subject may have multiple myeloma, may be suspected of having multiple myeloma, or may be at risk of developing multiple myeloma. In other instances, a subject may be a healthy normal subject not having a particular disease (e.g., a control subject).

[0032] The term “sample” or “test sample” as used herein can mean any sample in which the presence and / or level of an analyte or biomarker is to be detected or determined. Samples may include liquids, solutions, emulsions, or suspensions. Samples may include a medical sample or a biological sample. Samples may include any biological fluid or tissue, such as blood, whole blood, peripheral (i.e., circulating) blood, blood fractions of blood such as plasma and serum, muscle, interstitial fluid, sweat, saliva, urine, tears, synovial fluid, bone marrow (e.g., bone marrow aspirate), cerebrospinal fluid, nasal secretions, sputum, amniotic fluid, bronchoalveolar lavage fluid, gastric lavage, emesis, fecal matter, lung tissue, peripheral blood mononuclear cells, total white blood cells, lymph node cells, spleen cells, tonsil cells, cancer cells, tumor cells, bile, digestive fluid, skin, or combinations thereof. Samples can be obtained by any means known in the art.

[0033] The terms “control,” “baseline,” “baseline level,” “reference level,” and “reference” may be used herein interchangeably. A control may include a control subject, a control group, or a control sample therefrom, whose disease state is known. For example, the control subject, or sample therefrom, may be healthy, diseased, diseased prior to treatment, diseased during treatment, or diseased after treatment, or a combination thereof.

[0034] The terms “correlated with” or “associated with” may be used herein interchangeably and refer to the levels of HAPLN 1 protein in a biological sample of a subj ect that has a statistically significant correlation with a physiological state (e.g., multiple myeloma disease status or extent of the disease, response to treatment, and survival). The strength of the correlation or association between HAPLN1 protein levels and the presence or absence of a particular physiological state may be determined by a statistical test of significance known in the art.

[0035] The term “treatment” or “treating” as used herein refers to prophylaxis of, preventing, suppressing, repressing, reversing, alleviating, ameliorating, or inhibiting the progress of a disease or condition, or completely eliminating a disease or condition. A treatment may be performed in an acute or chronic way. The term “treatment” also refers to reducing the severity of a disease or symptoms associated with such disease prior to affliction with the disease. Preventing the disease can involve diagnosing a disease and administering a therapeutic composition or treatment to aAtty Docket Nos. P250229W001 | 218707-0027-W001subject prior to onset of the disease. Suppressing the disease can involve administering a therapeutic composition or treatment to a subject after induction of the disease but before its clinical appearance. Repressing or ameliorating the disease can involve administering a therapeutic composition or treatment to a subject after clinical appearance of the disease.

[0036] The term “administration” or “administering” as used herein refers to providing, contacting, and / or delivery of an action, agent, composition, cell, or other treatment by any appropriate route to achieve a desired effect. Exemplary modes of administration may include, but are not limited to, oral, sublingual, parenteral, enteral, transdermal, topical, buccal, rectal, vaginal, nasal, ophthalmic, inhalation, and implants. The term “parenterally” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrastemal, subcutaneous, and intraarticular injection and infusion. Via the parenteral route, the treatment may be in the form of solutions or suspensions for infusion or injection, or as lyophilized powders. Via the enteral route, the treatment may be in the form of capsules, gel capsules, tablets, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, or microspheres, nanospheres, lipid vesicles, or polymer vesicles allowing for controlled release. Via the topical route, the treatment may be in the form of an aerosol, spray, powder, lotion, cream, paste, gel, ointment, oil, suspensions, solutions, or emulsions.

[0037] The term “therapeutically effective amount” as used herein refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of a multiple myeloma treatment disclosed herein may be determined by a person skilled in the art and may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the treatment to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of a multiple myeloma treatment of the disclosure are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose of a multiple myeloma treatment disclosed herein is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0038] The term “standard multiple myeloma treatment” as used herein refers to the clinically established “standard of care” for newly diagnosed multiple myeloma subjects as known to thoseAtty Docket Nos. P250229W001 | 218707-0027-W001skilled in the art. A standard multiple myeloma treatment may also be referred to as a “first-line therapy.”

[0039] The term “non-standard multiple myeloma treatment” as used herein refers to any alternative or deviation from the clinically established “standard of care” for newly diagnosed multiple myeloma subjects as known to those skilled in the art. A non-standard multiple myeloma treatment may also be referred to as a “second-line therapy.”II. HAPLN1 Protein Biomarkers

[0040] Disclosed herein are HAPLN1 protein biomarkers that may be detectable in peripheral blood samples and suitable for determining multiple myeloma prognosis, diagnosis, and / or treatment for a subject. Exemplary HAPLN1 protein biomarkers are described below.

[0041] Hyaluronan and proteoglycan link protein 1 (HAPLN1) is an ECM protein most studied for its role in maintaining cartilage structure. HAPLN1 is particularly known to be produced and secreted by bone marrow stromal cells (BMSCs) and primarily resides in the bone marrow and bone tissue microenvironments. Bone marrow HAPLN1 protein has been shown to promote NF-KB activity, malignancy, and drug resistance in multiple myeloma cells. Elevated levels of HAPLN1 protein in bone marrow have also been shown to be associated with poor prognosis of patients with newly diagnosed multiple myeloma.

[0042] As disclosed herein, HAPLN1 protein levels were surprisingly and unexpectedly found to be detectable and measurable at high levels in peripheral blood samples from multiple myeloma subjects.

[0043] The full-length sequence of human HAPLN1 protein is 354 amino acids and includes an N-terminal signal peptide followed by 3 structural domains, the immunoglobulin (Ig)-like (IG) domain and the proteoglycan tandem repeat 1 and 2 domains (PTR1 and PTR2) (see Table 1, SEQ ID NO: 1). In Table 1, the IG domain (100 amino acids) is provided as SEQ ID NO: 11, the PTR1 domain (95 amino acids) is provided as SEQ ID NO: 12, and the PTR2 domain (91 amino acids) is provided as SEQ ID NO: 13. The N-terminal signal peptide is 15 amino acids long and is known to be cleaved from the full-length protein during secretion to the ECM (see Table 1, SEQ ID NO: 2). The IG domain binds to proteoglycans, such as aggrecan, while the PTR1 and PTR2 domains bind to hyaluronic acid (HA) to create cartilage ECM.Atty Docket Nos. P250229W001 | 218707-0027-W001

[0044] Various functional truncated matrikines of HAPLN1 are also generated due to proteolytic cleavage by matrix metalloproteinase enzymes (e.g., MMP-2). These HAPLN1 matrikines are bioactive fragments that have been shown to enhance multiple myeloma cell malignancy and therapeutic drug resistance in the bone marrow environment by promoting oncogenic cell signaling pathways, such as NF-KB.

[0045] The length of generated HAPLN1 matrikine depends on the specific MMP cleavage site. For example, the longest known HAPLN1 matrikine is formed by MMP-2 cleavage between the N-terminal signal peptide and the IG domain. This long HAPLN1 matrikine is 323 amino acids and includes the IG, PTR1, and PTR2 domains (see Table 1, SEQ ID NO: 3).

[0046] Another cleavage by MMP-2 between the IG and PTR1 domains (within the “ALDLQG” interdomain region) produces a shorter HAPLN1 matrikine that includes the PTR1 and PTR2 domains. However, the precise location of the cleavage site remains uncharacterized. Thus, different length variants of the shorter HAPLN1 matrikine ranging from 202 to 196 amino acids may be generated and are provided in Table 1 as SEQ ID NOs: 4-10, based on the seven potential cleavage sites within the interdomain region. Each one of these shorter HAPLN1 matrikines includes both the PTR1 and PTR2 domains.

[0047] In various instances, the methods described herein may detect a level of HAPLN1 protein that comprises full-length HAPLN1, a HAPLN1 matrikine, a functional HAPLN1 domain or variant thereof, or combinations thereof.

[0048] In various instances, the detected HAPLN1 protein may comprise an amino acid sequence having at least 95% identity to any one of SEQ ID NOs: 1-13.Table 1. Amino acid sequences of human HAPLN1 protein and matrikines.Atty Docket Nos. P250229W001 | 218707-0027-W001Atty Docket Nos. P250229W001 | 218707-0027-W001III. Methods of Determining Multiple Myeloma Prognosis, Diagnosis, and Treatment

[0049] Disclosed herein are methods of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma based on the detection of HAPLN1 protein levels in peripheral blood samples. Also disclosed herein are methods of determining a multiple myeloma treatment based on the detection of HAPLN1 protein levels in peripheral blood samples. Various aspects of exemplary methods are described below.a. Methods of sample collection

[0050] In various instances, the methods may comprise collecting a peripheral blood sample from a subject. As used herein, “peripheral blood” may also refer to “circulating blood.” For example, a “peripheral blood sample” as used herein refers to a sample of circulating blood collected from the general vascular system in a subject’s body that includes arteries, capillaries, and veins, rather than blood that is concentrated within a specific organ.Atty Docket Nos. P250229W001 | 218707-0027-W001

[0051] In some instances, the peripheral blood sample may be a whole blood sample, a plasma sample, or a serum sample.

[0052] In some instances, collecting the peripheral blood sample from the subject comprises venipuncture, capillary sampling, or a combination thereof. One non-limiting example of venipuncture includes drawing peripheral blood from a vein. One non-limiting example of capillary sampling includes drawing peripheral blood from a finger or heel.

[0053] In some instances, the peripheral blood sample may be used and analyzed directly as obtained from a patient or may be pre-treated, such as by filtration, isolation, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the blood sample in some manner as discussed herein or otherwise as is known in the art.

[0054] Peripheral blood samples may also be combined with various components following collection to preserve or prepare samples for subsequent assay techniques. For example, in some instances, blood samples may be treated with an anticoagulant, a cell fixative, a protease inhibitor, a phosphatase inhibitor, a protein, a DNA, or an RNA preservative following collection. In some instances, a peripheral blood sample may be collected via venipuncture using vacuum collection tubes containing an anticoagulant such as EDTA or heparin. Blood can also be collected using a heparin-coated syringe and hypodermic needle.

[0055] In some instances, a bone marrow sample is collected from the subject prior to collecting the peripheral blood sample from the subject. Bone marrow samples (e.g., bone marrow aspirates) may be extracted (i.e., “pulled”) and collected using methods known in the art. In some instances, a single bone marrow sample may be pulled and collected from the subject prior to collecting the peripheral blood sample. In other instances, multiple bone marrow samples may be pulled and collected from the subject prior to collecting the peripheral blood sample. In other instances, one or more bone marrow samples may be collected from a subject after one or more peripheral blood samples have been collected from the subject.

[0056] In some instances, when a bone marrow sample is collected from the subject prior to collecting the peripheral blood sample from the subject, the methods described herein may further comprise detecting a level of HAPLN 1 protein in the bone marrow sample and comparing the level of the HAPLN1 protein in the bone marrow sample to the level of the HAPLN1 protein in the peripheral blood sample. In other instances, when a bone marrow sample is collected from theAtty Docket Nos. P250229W001 | 218707-0027-W001subject after collecting the peripheral blood sample from the subject, the methods described herein may further comprise detecting a level of HAPLN1 protein in the bone marrow sample and comparing the level of the HAPLN1 protein in the bone marrow sample to the level of the HAPLN 1 protein in the peripheral blood sample.

[0057] In some instances, a single peripheral blood sample may be collected from the subject. In other instances, multiple peripheral blood samples may be collected from the subject. In some instances, a single peripheral blood sample may be collected from a subject with or without a prior collection of one or more bone marrow samples. In other instances, multiple peripheral blood samples may be collected from a subject with or without a prior collection of one or more bone marrow samples. The particular sequence or order in which one or more peripheral blood and bone marrow samples are collected from a subject may vary depending on the specific case.

[0058] In some instances, a peripheral blood sample is collected from a subject after the subject has been treated with at least one multiple myeloma treatment. In other instances, a peripheral blood sample is collected from a subject who has not received any type of multiple myeloma treatment. In some instances, a bone marrow sample is collected from a subject after the subject has been treated with at least one multiple myeloma treatment. In other instances, a bone marrow sample is collected from a subject who has not received any type of multiple myeloma treatment.

[0059] In some instances, a subject may be administered one or more multiple myeloma treatments prior to or following the collection of one or more peripheral blood and / or bone marrow samples. In certain instances, a peripheral blood sample and a bone marrow sample may be collected from a subject that was administered one or more multiple myeloma treatments in the period of time between collection of these different samples.b. Methods of detecting HAPLN 1 protein levels

[0060] In various instances, the methods may comprise detecting a level of HAPLN1 protein in the peripheral blood sample. In certain instances, the HAPLN 1 protein being detected may comprise full-length HAPLN1, a HAPLN1 matrikine, a functional HAPLN 1 domain or variant thereof, or combinations thereof. In certain instances, the HAPLN1 protein being detected may comprise an amino acid sequence having at least 95% identity to any one of SEQ ID NOs: 1-13.

[0061] In some instances, HAPLN1 protein levels may be detected directly from a peripheral blood sample without isolation or enrichment. In other instances, HAPLN 1 protein may be isolated or enriched from a peripheral blood sample using methods known in the art prior to detection.Atty Docket Nos. P250229W001 | 218707-0027-W001

[0062] In some instances, detecting the level of HAPLN 1 protein in the peripheral blood sample may comprise an immunoassay, mass spectrometry, a microarray, or combinations thereof. It will be understood, however, that any clinically relevant protein detection assays known in the art may also be used in the methods described herein to detect and measure HAPLN 1 protein levels.

[0063] In some instances, the immunoassay may comprise an ELISA assay, a competitive or inhibition ELISA assay, a sandwich ELISA assay, an ELISA microarray, an amplified luminescent proximity homogenous assay-linked immunosorbent assay, a bioluminescence assay, a fluorescence resonance energy transfer (FRET) immunoassay, a lateral flow immunoassay, or combinations thereof. In particular embodiments, detection of HAPLN1 protein levels is performed using an immunoassay with one or more antibodies that are specific to HAPLN 1 protein (i.e., an anti-HAPLNl antibody).

[0064] In some instances, the immunoassay may comprise HAPLN1 polyclonal antibodies, HAPLN 1 monoclonal antibodies, or a combination thereof. The antibodies specific to HAPLN 1 protein may recognize one or more epitopes of a HAPLN1 protein antigen, including epitopes corresponding to specific HAPLN1 domain regions such as the IG domain, PTR1 domain, and / or PTR2 domain.

[0065] The immunoassays may be homogeneous or heterogeneous assays, competitive or noncompetitive assays. The immunoassay may be in the form of a sandwich assay, which is a noncompetitive immunoassay, wherein a HAPLN1 protein molecule to be detected and / or quantified is bound to a first HAPLN1 antibody and to a second HAPLN1 antibody. The first antibody may be bound to a solid phase, e.g., a bead, a surface of a well or other container, a chip or a strip, and the second antibody is an antibody that is labeled, e.g., with a dye, with a radioisotope, or a reactive or catalytically active moiety or vice versa. The amount of labeled antibody bound to a HAPLN1 protein analyte is then measured by an appropriate method known in the art. The general composition and procedures involved with “sandwich assays” are well-established and known to the skilled person.

[0066] For example, the immunoassay may comprise two HAPLN1 antibodies which are both present as dispersions in a liquid reaction mixture or one of the antibodies (e.g., a first HAPLN1 antibody) may be labeled and the other antibody (e.g., a second HAPLN1 antibody) may be bound to a solid phase or may be bound selectively to a solid phase wherein a first labelling componentAtty Docket Nos. P250229W001 | 218707-0027-W001is attached to the first antibody, wherein the first labelling component is part of a labelling system based on fluorescence- or chemiluminescence-quenching or amplification, and a second labelling component of the labelling system is attached to the second antibody, so that upon binding of both antibody capture molecules to the HAPLN1 protein analyte, a measurable signal is generated that allows for the detection of the formed sandwich complexes in the sample solution comprising the HAPLN1 protein.

[0067] Immunoassays described herein may include the use of standards, or known concentrations of a HAPLN1 protein analyte, to generate a calibration or standard curve. This standard curve allows for the quantification of HAPLN1 protein levels from unknown samples by comparing the detected signals (e.g., fluorescence, absorbance, luminescence) in the unknown sample to those of the standards. Different modeling strategies known in the art including, but not limited to, four-parameter or five-parameter logistic curve-fitting models can be used to calculate detected HAPLN1 protein levels from unknown samples based on generated standard curves.

[0068] Fluorescence based immunoassays may comprise the use of dyes, which may include, but are not limited to, FAM (5-or 6-carboxyfluorescein), VIC, NED, Fluorescein, Fluoresceinisothiocyanate (FITC), IRD-700 / 800, Cyanine dyes, such as CY3, CYS, CY3.5, CY5.5, Cy7, Xanthen, 6-Carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), TET, 6-Carboxy-4',5'-dichloro-2',7'-dimethodyfluorescein (JOE), N, N, N', N'-Tetramethyl-6-carboxyrhodamine (TAMRA), 6-Carboxy-X-rhodamine (ROX), 5-Carboxyrhodamine-6G (R6G5), 6-carboxyrhodamine-6G (RG6), Rhodamine, Rhodamine Green, Rhodamine Red, Rhodamine 110, BODIPY dyes, such as BODIPY TMR, Oregon Green, Coumarins such as Umbelliferone, Benzimides, such as Hoechst 33258; Phenanthridines, such as Texas Red, Yakima Yellow, Alexa Fluor, PET, Ethidiumbromide, Acridinium dyes, Carbazol dyes, Phenoxazine dyes, Porphyrine dyes, or Poly methin dyes.

[0069] Chemiluminescence based immunoassays may comprise the use of dyes, which may include, but are not limited to, acridinium esters, dioxetanes, or luminol.

[0070] In certain non-limiting exemplary aspects, an amplified luminescent proximity homogenous assay-linked immunosorbent assay (e.g., AlphaLISA®, Revvity, Inc.) is used to detect and measure HAPLN1 protein levels. The amplified luminescent proximity homogenous assay-linked immunosorbent assay is a homogeneous immunoassay technology that uses donorAtty Docket Nos. P250229W001 | 218707-0027-W001and acceptor beads and multiple analyte-specific antibodies to detect target analytes in a sample, without the need for any washing steps, providing a sensitive and rapid immunoassay platform.

[0071] In various instances, concentration levels of detected HAPLN1 protein in peripheral blood samples may include any detectable and quantifiable value measured using a protein detection assay or method disclosed herein. For instance, exemplary concentration levels of detected HAPLN1 protein in peripheral blood may range from about 0.01 pg / mL to about 5.0 pg / mL. In various instances, exemplary concentration levels of detected HAPLN1 protein in peripheral blood may be from 0.05 pg / mL to 4.5 pg / mL; 0.1 pg / mL to 4.0 pg / mL; 0.25 pg / mL to 3.5 pg / mL; 0.5 pg / mL to 3.0 pg / mL; 0.75 pg / mL to 2.5 pg / mL; 0.9 pg / mL to 2.25 pg / mL; 0.95 pg / mL to 2.1 pg / mL; 1.0 pg / mL to 2.0 pg / mL; 1.05 pg / mL to 1.95 pg / mL; 1.1 pg / mL to 1.9 pg / mL; or 1.25 pg / mL to 1.75 pg / mL. In some instances, the concentration level of detected HAPLN1 protein in peripheral blood may be less than about 0.01 pg / mL. For example, the concentration level of detected HAPLN1 protein in peripheral blood may be as low as 0.001 pg / mL, or even less. In some instances, the concentration level of detected HAPLN1 protein in peripheral blood may be greater than about 5.0 pg / mL. For example, the concentration level of detected HAPLN1 protein in peripheral blood may be as high as 10.0 pg / mL, or even greater.

[0072] It will be understood, however, that the specific concentration levels of detected FIAPLN1 protein in peripheral blood samples measured using the assays and methods disclosed herein will vary and depend upon a variety of factors including, but not limited to, the age, sex, lifestyle, and disease state / severity of the subject, whether the subject has been administered any multiple myeloma treatments, and the sensitivity and specificity of the particular protein detection assay employed. For example, newly diagnosed multiple myeloma patients (i.e., diagnosed within 6 months to 1 year) may have lower concentration levels of HAPLN1 protein in peripheral blood as compared to later stage or more severe multiple myeloma patients, such as patients with relapsed / refractory multiple myeloma (RRMM).c. Baseline levels of HAPLN1 protein in control samples

[0073] In various instances, the methods may comprise comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample. A determination of multiple myeloma prognosis, diagnosis, and / or treatment can then be made for the subject.Atty Docket Nos. P250229W001 | 218707-0027-W001

[0074] In some instances, the baseline level of HAPLN1 protein in a control sample is determined using any of the protein detection methods or assays disclosed above.

[0075] In some instances, the control sample may be a peripheral blood sample from a subject not having multiple myeloma.

[0076] The baseline level of HAPLN1 protein in the control sample may be a predetermined value or range based on a calculated average from a control group of subjects, which is then employed as a benchmark against which to compare and assess a measured level of HAPLN1 protein in a subject. In some instances, the baseline level of HAPLN1 protein from a control sample may represent a clinical “threshold value” of HAPLN1 protein level in a peripheral blood sample for determining a multiple myeloma prognosis, diagnosis, and / or treatment. For example, when a detected level of HAPLN1 protein in a peripheral blood sample from a subject exceeds such a clinical threshold value to a significant degree (i.e., statistically significant), a determination of multiple myeloma prognosis, diagnosis, and / or treatment can be made.

[0077] The baseline level of HAPLN1 protein in a control sample may vary based on certain factors such as, for example, the age, sex, diet, lifestyle, comorbidities, and / or overall health of the control subject from which the control sample is derived. For example, baseline levels of HAPLN1 protein may be relatively higher or lower in older subjects (e.g., 60 years old or greater) as compared to younger subjects (e.g., less than 60 years old). These factors should be accounted for in the methods described herein at least by using age- and sex -matched control samples when comparing detected HAPLN1 protein levels from a subject to baseline HAPLN1 levels in a control sample from a control subject or group.

[0078] For example, in various instances, a subject may be age-matched with a control subject or control group of the same age or same average age, an age or average age within 1 year of the subject, an age or average age within 2 years of the subject, an age or average age within 3 years of the subject, an age or average age within 4 years of the subject, an age or average age within 5 years of the subject, an age or average age within 6 years of the subject, an age or average age within 7 years of the subject, an age or average age within 8 years of the subject, an age or average age within 9 years of the subject, or an age or average age within 10 years of the subj ect.Atty Docket Nos. P250229W001 | 218707-0027-W001d. Methods of determining multiple myeloma prognosis and diagnosis

[0079] In various instances, when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the methods may comprise: determining a first multiple myeloma prognosis for the subject related to subject outcome, determining a second multiple myeloma prognosis for the subject related to treatment response, determining the subject as having multiple myeloma, or combinations thereof.

[0080] A person skilled in the art will understand that a first and / or second multiple myeloma prognosis is determined for a subject who has already been clinically determined as having multiple myeloma (i.e., is diagnosed with multiple myeloma).

[0081] In some instances, the first multiple myeloma prognosis for the subject may comprise a reduced progression-free survival. “Progression-free survival” as used herein refers to the length of time a subject survives without their multiple myeloma progressing / worsening after being diagnosed with multiple myeloma or after starting a multiple myeloma treatment. As the skilled person will appreciate, a patient’s progression-free survival is reduced if the patient experiences a shorter length of time during which the disease does not progress as compared to an average or median progression-free survival time of a control group of patients. In contrast, a patient’s progression-free survival is improved or enhanced if the patient experiences a longer length of time during which the disease does not progress as compared to an average or median progression-free survival time of a control group of patients.

[0082] In some instances, the first multiple myeloma prognosis for the subject may comprise other prognoses related to subject outcome including, but not limited to, reduced quality of life, increased disease progression, increased risk of relapsed or refractory disease, increased cytogenic risk, reduced remission duration, and / or reduced overall survival relative to a control group of patients.

[0083] In some instances, the second multiple myeloma prognosis for the subject comprises drug resistance to a standard multiple myeloma treatment, the standard multiple myeloma treatment comprising bortezomib, lenalidomide, dexamethasone, an anti-CD38 antibody, autologous stem cell transplantation, or combinations thereof.

[0084] Additional criteria for multiple myeloma prognoses, subject outcomes, and treatment responses that are applicable to the methods disclosed herein are described and defined by the International Myeloma Working Group Uniform Response (IMWG), as disclosed in Durie et al.,Atty Docket Nos. P250229W001 | 218707-0027-W001Leukemia 2006, 20(9): 1467-73, Durie et al., Leukemia 2015, 29:2416-7, and Kumar et al., Lancet Oncol. 2016, 17:e328-46, each of which is incorporated herein by reference in its entirety. These criteria may include objective response, complete response, partial response, clinical relapse, progressive disease, and others.e. Methods of determining multiple myeloma treatment

[0085] In various instances, the methods may comprise determining an appropriate multiple myeloma treatment for the subject based on the level of the HAPLN1 protein in the peripheral blood sample relative to the baseline level of HAPLN1 protein in the control sample; wherein when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a non-standard multiple myeloma treatment; or wherein when the level of HAPLN1 protein in the peripheral blood sample is not greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a standard multiple myeloma treatment.

[0086] In some instances, the standard multiple myeloma treatment comprises bortezomib, lenalidomide, dexamethasone, an anti-CD38 antibody, autologous stem cell transplantation, or combinations thereof. A standard multiple myeloma treatment that includes a combination of bortezomib (Velcade®), lenalidomide (Revlimid®), and dexamethasone is commonly referred to as “VRd” treatment in clinical practice. This three-drug treatment regimen is often used as a first-line treatment option for newly diagnosed patients, particularly in patients who are eligible for autologous stem cell transplantation. This VRd drug combination is also commonly combined with an anti-CD38 antibody therapy (e.g., daratumumab) for newly diagnosed patients.

[0087] In some instances, the proteasome inhibitor, carfilzomib, may also be combined with one or more of lenalidomide, dexamethasone, an anti-CD38 antibody, or autologous stem cell transplantation as part of a standard multiple myeloma treatment. The term “anti-CD38 antibody” as used herein encompasses all antibodies that bind CD38 with sufficient affinity such that the antibody is useful as a therapeutic agent in targeting a multiple myeloma cell expressing the antigen. For example, an anti-CD38 antibody may bind to CD38 on the surface of a multiple myeloma cell and mediate cell lysis through the activation of complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosisAtty Docket Nos. P250229W001 | 218707-0027-W001(ADCP), and apoptosis mediated by Fc cross-linking, leading to a depletion of malignant multiple myeloma cells.

[0088] In some instances, the non-standard multiple myeloma treatment may comprise carfilzomib, selinexor, chimeric antigen receptor (CAR) T-cell therapy, pomalidomide, or combinations thereof. A non-standard multiple myeloma treatment may also be combined with any one or more of the standard multiple myeloma treatments described above.

[0089] In some instances, a non-standard multiple myeloma treatment is administered to a subject due to an observed or predicted drug resistance of the subject to a standard multiple myeloma treatment as described herein. For example, subjects having elevated levels of HAPLN1 protein in their peripheral blood as compared to a control may exhibit resistance to standard multiple myeloma treatments (e.g., VRd treatment) but be more susceptible and responsive to one or more non-standard multiple myeloma treatments described herein, such as carfilzomib and selinexor.

[0090] In the methods described herein, one or more additional multiple myeloma treatments may be administered to a subject simultaneously or sequentially with the disclosed standard and non-standard multiple myeloma treatments. For example, in some instances, a subject may be further administered a therapeutically effective amount of an additional multiple myeloma treatment, the additional multiple myeloma treatment comprising a proteasome inhibitor, a nuclear export inhibitor, a steroid, an immunomodulatory drug, a DNA damaging agent, a chemotherapy, an antibody, radiation, a BCL-2 inhibitor, CAR T-cell therapy, autologous stem cell transplantation, or combinations thereof. Sequential administration includes administration before or after the administration of the disclosed standard and non-standard multiple myeloma treatments.

[0091] In some instances, a disclosed standard or non-standard multiple myeloma treatment and additional multiple myeloma treatment(s) may be administered in the same composition. In other instances, there may be an interval of time between administration of the disclosed standard or non-standard multiple myeloma treatment and any additional multiple myeloma treatment s). In some instances, administration of an additional multiple myeloma treatment with a disclosed standard or non-standard multiple myeloma treatment may allow lower doses of the additional multiple myeloma treatment and / or the disclosed standard or non-standard multiple myeloma treatment, and / or may allow administration at less frequent intervals. When used in combination,Atty Docket Nos. P250229W001 | 218707-0027-W001the disclosed standard and non-standard multiple myeloma treatments and the additional multiple myeloma treatments may be used in lower doses than when each is used singly. It will be understood that any combination of one or more standard, non-standard, or additional multiple myeloma treatments disclosed herein may be administered to a subject.

[0092] In various instances, a therapeutically effective amount of any of the multiple myeloma treatments disclosed herein may be about 1 mg / kg to about 1000 mg / kg, about 5 mg / kg to about 950 mg / kg, about 10 mg / kg to about 900 mg / kg, about 15 mg / kg to about 850 mg / kg, about 20 mg / kg to about 800 mg / kg, about 25 mg / kg to about 750 mg / kg, about 30 mg / kg to about 700 mg / kg, about 35 mg / kg to about 650 mg / kg, about 40 mg / kg to about 600 mg / kg, about 45 mg / kg to about 550 mg / kg, about 50 mg / kg to about 500 mg / kg, about 55 mg / kg to about 450 mg / kg, about 60 mg / kg to about 400 mg / kg, about 65 mg / kg to about 350 mg / kg, about 70 mg / kg to about 300 mg / kg, about 75 mg / kg to about 250 mg / kg, about 80 mg / kg to about 200 mg / kg, about 85 mg / kg to about 150 mg / kg, or about 90 mg / kg to about 100 mg / kg. In various instances, a therapeutically effective amount of any of the multiple myeloma treatments disclosed herein may be no greater than about 1000 mg / kg; no greater than about 900 mg / kg; no greater than about 800 mg / kg; no greater than about 700 mg / kg; no greater than about 600 mg / kg; no greater than about 500 mg / kg; no greater than about 400 mg / kg; no greater than about 300 mg / kg; no greater than about 200 mg / kg; no greater than about 100 mg / kg; no greater than about 90 mg / kg; no greater than about 80 mg / kg; no greater than about 70 mg / kg; no greater than about 60 mg / kg; no greater than about 50 mg / kg; no greater than about 40 mg / kg; no greater than about 30 mg / kg; or no greater than about 20 mg / kg. In various instances, a therapeutically effective amount of any of the multiple myeloma treatments disclosed herein may be no less than about 1 mg / kg; no less than about 5 mg / kg; no less than about 10 mg / kg; no less than about 20 mg / kg; no less than about 30 mg / kg; no less than about 40 mg / kg; no less than about 50 mg / kg; no less than about 60 mg / kg; no less than about 70 mg / kg; no less than about 80 mg / kg; no less than about 90 mg / kg; no less than about 100 mg / kg; no less than about 200 mg / kg; no less than about 300 mg / kg; no less than about 400 mg / kg; no less than about 500 mg / kg; no less than about 600 mg / kg; no less than about 700 mg / kg; no less than about 800 mg / kg; or no less than about 900 mg / kg.

[0093] In various instances, a therapeutically effective amount of any of the multiple myeloma treatments disclosed herein may be about 1 mg / day to about 1000 mg / day, about 5 mg / day to about 950 mg / day, about 10 mg / day to about 900 mg / day, about 15 mg / day to about 850 mg / day, aboutAtty Docket Nos. P250229W001 | 218707-0027-W00120 mg / day to about 800 mg / day, about 25 mg / day to about 750 mg / day, about 30 mg / day to about 700 mg / day, about 35 mg / day to about 650 mg / day, about 40 mg / day to about 600 mg / day, about 45 mg / day to about 550 mg / day, about 50 mg / day to about 500 mg / day, about 55 mg / day to about 450 mg / day, about 60 mg / day to about 400 mg / day, about 65 mg / day to about 350 mg / day, about 70 mg / day to about 300 mg / day, about 75 mg / day to about 250 mg / day, about 80 mg / day to about 200 mg / day, about 85 mg / day to about 150 mg / day, or about 90 mg / day to about 100 mg / day. In various instances, a therapeutically effective amount of any of the multiple myeloma treatments disclosed herein may be no greater than about 1000 mg / day; no greater than about 900 mg / day; no greater than about 800 mg / day; no greater than about 700 mg / day; no greater than about 600 mg / day; no greater than about 500 mg / day; no greater than about 400 mg / day; no greater than about 300 mg / day; no greater than about 200 mg / day; no greater than about 100 mg / day; no greater than about 90 mg / day; no greater than about 80 mg / day; no greater than about 70 mg / day; no greater than about 60 mg / day; no greater than about 50 mg / day; no greater than about 40 mg / day; no greater than about 30 mg / day; or no greater than about 20 mg / day. In various instances, a therapeutically effective amount of any of the multiple myeloma treatments disclosed herein may be no less than about 1 mg / day; no less than about 5 mg / day; no less than about 10 mg / day; no less than about 20 mg / day; no less than about 30 mg / day; no less than about 40 mg / day; no less than about 50 mg / day; no less than about 60 mg / day; no less than about 70 mg / day; no less than about 80 mg / day; no less than about 90 mg / day; no less than about 100 mg / day; no less than about 200 mg / day; no less than about 300 mg / day; no less than about 400 mg / day; no less than about 500 mg / day; no less than about 600 mg / day; no less than about 700 mg / day; no less than about 800 mg / day; or no less than about 900 mg / day.

[0094] In various instances, a subject may be administered a single dose of any of the multiple myeloma treatments disclosed herein. In other embodiments, a subject may be administered a plurality of doses over a period of time. For example, in various instances, a multiple myeloma treatment as disclosed herein may be administered to a subject once a day (SID / QD), twice a day (BID), three times a day (TID), four times a day (QID), or more, so as to administer a therapeutically effective amount to the subject, where the therapeutically effective amount is any one or more of the doses described herein. In some instances, a multiple myeloma treatment as disclosed herein is administered to a subject 1-3 times per day, 1-7 times per week, 1-9 times per month, 1-12 times per year, or more. In some instances, a multiple myeloma treatment as disclosedAtty Docket Nos. P250229W001 | 218707-0027-W001herein is administered to a subject for about 1-10 days, 10-20 days, 20-30 days, 30-40 days, 40-50 days, 50-60 days, 60-70 days, 70-80 days, 80-90 days, 90-100 days, 1-6 months, 6-12 months, 1-5 years, or more.

[0095] The dosage regimens described herein may be adjusted to provide an optimal therapeutic response. It will be understood, however, that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the dosage form of the specific multiple myeloma treatment employed, the administration protocol of the specific multiple myeloma treatment employed, the metabolic stability and length of action of the specific multiple myeloma treatment, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, severity of the particular multiple myeloma condition, and the particular subject undergoing therapy.IV. Kits

[0096] Also provided herein are assay kits, which may be used to perform the methods disclosed herein to selectively detect HAPLN1 protein levels in a peripheral blood sample from a subject. In some aspects, the kit may be an immunoassay kit comprising one or more anti-HAPLN 1 antibodies as described herein, a detection reagent, and instructions for using the kit. The kit may further comprise one or more solid supports (e.g., beads) for an anti-HAPLNl antibody. The kit may also comprise a detection means. The kit may also comprise a means for collecting and / or processing a peripheral blood sample.

[0097] The kits may comprise information, instructions, or both that use of the kit will provide treatment for medical conditions in mammals (particularly humans). The information and instructions may be in the form of words, pictures, or both, and the like.V. Clinical Assay Performance

[0098] The methods and assays disclosed herein may be used in clinical practice to diagnose or prognose multiple myeloma in a subject, identify a subject at risk of multiple myeloma, and / or determine a therapeutic treatment regimen for a subject having multiple myeloma. In some instances, clinical assay performance can be assessed by determining an assay's sensitivity, specificity, area under the ROC curve (AUC), accuracy, positive predictive value (PPV), and negative predictive value (NPV).Atty Docket Nos. P250229W001 | 218707-0027-W001

[0099] The terms “sensitivity” and “specificity” as used herein with regard to a multiple myeloma diagnostic and / or prognostic assay depend on more than just the analytical “quality” of the test, they also depend on the definition of what constitutes an abnormal result. In practice, Receiver Operating Characteristic curves (ROC curves) are typically calculated by plotting the value of a variable versus its relative frequency in “normal” (i.e., apparently healthy individuals not having a particular disorder or condition) and “disease” populations. For any particular biomarker, a distribution of biomarker levels for subjects with and without a disease will likely overlap. Under such conditions, a test does not absolutely distinguish a normal condition from a disease condition with 100% accuracy, and the area of overlap indicates where the test cannot distinguish normal from disease. A threshold may be selected, below which the test is considered to be abnormal / diseased and above which the test is considered to be normal, or vice versa.

[0100] The area under the ROC curve (AUC) is a measure of the probability that the perceived measurement will allow correct identification of a condition. ROC curves can be used even when test results do not necessarily give an accurate number. As long as one can rank results, one can create a ROC curve. For example, results of a test on “disease” samples might be ranked according to degree (e.g., l=low, 2=normal, and 3=high). This ranking can be correlated to results in the “normal” population, and a ROC curve created. These methods are well known in the art. For example, a threshold may be selected to provide a ROC curve area of greater than about 0.5, about 0.7, about 0.8, about 0.85, or about 0.9.

[0101] In some instances, the clinical performance of the assays described herein may be based on sensitivity. For example, the sensitivity of an assay may be at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In some instances, the clinical performance of the assays described herein may be based on specificity. For example, the specificity of an assay may be at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%. In some instances, the clinical performance of the assays described herein may be based on AUC. For example, the AUC of an assay may be at least about 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, or 0.95. In some instances, the clinical performance of the assays described herein may be based on accuracy. For example, accuracy of an assay may be at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%.Atty Docket Nos. P250229W001 | 218707-0027-W001VI. Examples

[0102] Without limiting the scope of the instant disclosure, various experimental examples of aspects and embodiments discussed above were prepared and the results are discussed below.Example 1: Detection of HAPLN1 protein levels in the peripheral blood of multiple myeloma patients

[0103] A bone marrow (BM) aspirate sample and a peripheral blood sample from the same multiple myeloma (MM) patient were obtained. The MM patient was a 77-year-old female diagnosed 11 months before the BM biopsy. The MM patient had previously been treated with daratumumab (anti-CD38 monoclonal antibody), bortezomib, and dexamethasone, and exhibited a partial remission at the time of sample collection. The BM aspirate sample was collected as a “second pull” BM sample about 15 minutes after an initial BM pull that was used for pathological diagnosis. The peripheral blood sample was then collected by venipuncture following the second pull and collection of the BM aspirate. The collected BM aspirate and peripheral blood samples were centrifuged at 400 x for 5 min at room temperature. The plasma layers from the BM aspirate and peripheral blood samples were collected, and stored at -80 °C for further analysis.

[0104] The plasma layers were then subjected to an amplified luminescent proximity homogenous assay-linked immunosorbent assay (AlphaLISA®, Revvity, Inc.) to detect HAPLN1 protein levels in the different samples. First, the samples were diluted 50x in PBS and the final IgG level was adjusted by adding human IgG isotype control (31154, Invitrogen, San Diego, CA, USA) to 1.1 mg / mL. The standard was prepared by making serial dilutions of recombinant HAPLN1 protein (10323-H08H, Sino Biological, Beijing, China) with standard diluent (FBS diluted 50x in PBS with human IgG isotype control added to 1.1 mg / mL). The AlphaLISA assay was performed using assay buffer (25 mM HEPES, 0.5% BSA, 0.5% Triton X-100, 1 pg / mL Dextran) at room temperature. FIG. 1 shows the standard curve of recombinant HAPLN1 protein concentration using the AlphaLISA immunoassay. The 50-fold diluted sample concentrations were calculated by interpolating from a 5-parameter logistic curve.

[0105] Diluted patient samples (5 pL) were then incubated with 7.5 ng each of 2 primary anti-HAPLNl antibodies reactive to human HAPLN1 protein, BAF2608 (R& D systems, Minneapolis, MN, USA) and HPA019105 (Sigma-Aldrich, St. Louis, MO, USA), for 30 min (15 pL totalAtty Docket Nos. P250229W001 | 218707-0027-W001volume) The BAF2608 primary' anti-HAPLNl antibody is a biotinylated polyclonal antibody from goat reactive against the long matrikine form of HAP LN 1 (amino acids 32-354; SEQ ID NO: 3), while the HPA019105 primary'- anti-HAPLNl antibody is a polyclonal antibody from rabbit reactive against the IG domain of HAPLN1 (SEQ ID NO: 11).

[0106] The secondary rabbit IgG acceptor bead (6760002S, Perkin Elmer, Waltham, MA, USA), 1 pg in 10 pL assay buffer, was added and incubated for 1 hour. Subsequently, the streptavidin donor bead (AL159C, Perkin Elmer, Waltham, MA, USA), 1 pg in 25 pL assay buffer, was added, and after 30 min of additional incubation, the samples were measured using an ENSPIRE plate reader (Perkin Elmer, Waltham, MA, USA). The measured HAPLN1 protein levels in the matched patient bone marrow and peripheral blood samples are shown below in Table 2.Table 2. Measured HAPLN1 protein concentrations in the bone marrow and peripheral blood of a multiple myeloma (MM) patient.

[0107] As shown above in Table 2, the bone marrow aspirate sample had a HAPLN1 protein concentration level of 2.45 pg / mL, while the peripheral blood sample had a HAPLN1 protein concentration level of 1.85 pg / mL. These results were surprising as it was unexpected that the detected levels of HAPLN1 protein in the peripheral blood would be almost as high as the detected levels of HAPLN1 protein in the bone marrow, or that peripheral blood HAPLN protein levels would be detectable at all.

[0108] HAPLN1 is an ECM protein most studied for its role in maintaining cartilage structure. The IG domain of HAPLN1 binds to proteoglycans, such as aggrecan, while the PTR domains of HAPLN1 bind to hyaluronic acid (HA) to create cartilage ECM, particularly in the bone marrow environment. There is no prior evidence, knowledge, or rationale to support or suggest that HAPLN1 protein in the peripheral blood of multiple myeloma patients would be detectable, let alone at such a high level.

[0109] It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which isAtty Docket Nos. P250229W001 | 218707-0027-W001defined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed aspects and embodiments will be apparent to those skilled in the art.VII. Embodiments

[0110] For reasons of completeness, representative non-limiting embodiments of the inventions described herein are set out in the following numbered embodiments.

[0111] Embodiment 1. A method of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma, the method comprising:collecting a peripheral blood sample from the subject;detecting a level of HAPLN1 protein in the peripheral blood sample;comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample; andwhen the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample:determining a first multiple myeloma prognosis for the subject related to subject outcome,determining a second multiple myeloma prognosis for the subject related to treatment response,determining the subject as having multiple myeloma,or combinations thereof.

[0112] Embodiment 2. The method of embodiment 1, wherein the peripheral blood sample is a whole blood sample, a plasma sample, or a serum sample.

[0113] Embodiment 3. The method of embodiment 1 or 2, wherein collecting the peripheral blood sample from the subject comprises venipuncture, capillary sampling, or a combination thereof.

[0114] Embodiment 4. The method of any one of embodiments 1-3, wherein the control sample is a peripheral blood sample from a subject not having multiple myeloma.

[0115] Embodiment 5. The method of any one of embodiments 1-4, wherein detecting the level of HAPLN1 protein in the peripheral blood sample comprises an immunoassay, mass spectrometry, a microarray, or combinations thereof.

[0116] Embodiment 6. The method of embodiment 5, wherein the immunoassay comprises anAtty Docket Nos. P250229W001 | 218707-0027-W001ELISA assay, a competitive or inhibition ELISA assay, a sandwich ELISA assay, an ELISA microarray, an amplified luminescent proximity homogenous assay-linked immunosorbent assay, a bioluminescence assay, a fluorescence resonance energy transfer (FRET) immunoassay, a lateral flow immunoassay, or combinations thereof

[0117] Embodiment 7. The method of embodiment 5 or 6, wherein the immunoassay comprises HAPLN1 polyclonal antibodies, HAPLN1 monoclonal antibodies, or a combination thereof.

[0118] Embodiment 8. The method of any one of embodiments 1-7, wherein the HAPLN1 protein comprises full-length HAPLN1, a HAPLN1 matrikine, a functional HAPLN1 domain or variant thereof, or combinations thereof.

[0119] Embodiment 9. The method of any one of embodiments 1-8, wherein the HAPLN1 protein comprises an amino acid sequence having at least 95% identity to any one of SEQ ID NOs: 1-13.

[0120] Embodiment 10. The method of any one of embodiments 1-9, wherein the first multiple myeloma prognosis for the subject comprises a reduced progression-free survival.

[0121] Embodiment 11. The method of any one of embodiments 1-10, wherein the method is repeated one or more times.

[0122] Embodiment 12. The method of any one of embodiments 1-11, wherein a bone marrow sample is collected from the subject prior to collecting the peripheral blood sample from the subject.

[0123] Embodiment 13. The method of embodiment 12, further comprising detecting a level of HAPLN1 protein in the bone marrow sample and comparing the level of the HAPLN1 protein in the bone marrow sample to the level of the HAPLN1 protein in the peripheral blood sample.

[0124] Embodiment 14. The method of any one of embodiments 1-13, wherein the second multiple myeloma prognosis for the subject comprises drug resistance to a standard multiple myeloma treatment, the standard multiple myeloma treatment comprising bortezomib, lenalidomide, dexamethasone, an anti-CD38 antibody, autologous stem cell transplantation, or combinations thereof.

[0125] Embodiment 15. The method of any one of embodiments 1-14, further comprising administering to the subject a therapeutically effective amount of a non-standard multiple myeloma treatment.Atty Docket Nos. P250229W001 | 218707-0027-W001

[0126] Embodiment 16. The method of embodiment 15, wherein the non-standard multiple myeloma treatment comprises carfilzomib, selinexor, chimeric antigen receptor (CAR) T-cell therapy, pomalidomide, or combinations thereof.

[0127] Embodiment 17. A method of determining treatment for a subject having multiple myeloma, the method comprising:collecting a peripheral blood sample from the subject;detecting a level of HAPLN1 protein in the peripheral blood sample;comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample; anddetermining an appropriate multiple myeloma treatment for the subject based on the level of the HAPLN1 protein in the peripheral blood sample relative to the baseline level of HAPLN1 protein in the control sample;wherein when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a non-standard multiple myeloma treatment; orwherein when the level of HAPLN1 protein in the peripheral blood sample is not greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a standard multiple myeloma treatment.

[0128] Embodiment 18. The method of embodiment 17, wherein the non-standard multiple myeloma treatment comprises carfilzomib, selinexor, chimeric antigen receptor (CAR) T-cell therapy, pomalidomide, or combinations thereof.

[0129] Embodiment 19. The method of embodiment 17 or 18, wherein the standard multiple myeloma treatment comprises bortezomib, lenalidomide, dexamethasone, an anti-CD38 antibody, autologous stem cell transplantation, or combinations thereof.

[0130] Embodiment 20. The method of any one of embodiments 17-19, wherein when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the subject has drug resistance to the standard multiple myeloma treatment.

[0131] Embodiment 21. The method of any one of embodiments 17-20, further comprising administering to the subject a therapeutically effective amount of an additional multiple myeloma treatment, the additional multiple myeloma treatment comprising a proteasome inhibitor, a nuclearAtty Docket Nos. P250229W001 | 218707-0027-W001export inhibitor, a steroid, an immunomodulatory drug, a DNA damaging agent, a chemotherapy, an antibody, radiation, a BCL-2 inhibitor, CAR T-cell therapy, autologous stem cell transplantation, or combinations thereof.

Claims

Atty Docket Nos. P250229W001 | 218707-0027-W001CLAIMS1. A method of determining a prognosis of a subject having multiple myeloma or identifying a subject as having multiple myeloma, the method comprising:collecting a peripheral blood sample from the subject;detecting a level of HAPLN1 protein in the peripheral blood sample;comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample; andwhen the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample:determining a first multiple myeloma prognosis for the subject related to subject outcome,determining a second multiple myeloma prognosis for the subject related to treatment response,determining the subject as having multiple myeloma,or combinations thereof.

2. The method of claim 1, wherein the peripheral blood sample is a whole blood sample, a plasma sample, or a serum sample.

3. The method of claim 1, wherein collecting the peripheral blood sample from the subject comprises venipuncture, capillary sampling, or a combination thereof.

4. The method of claim 1, wherein the control sample is a peripheral blood sample from a subject not having multiple myeloma.

5. The method of claim 1, wherein detecting the level of HAPLN1 protein in the peripheral blood sample comprises an immunoassay, mass spectrometry, a microarray, or combinations thereof.

6. The method of claim 5, wherein the immunoassay comprises an ELISA assay, aAtty Docket Nos. P250229W001 | 218707-0027-W001competitive or inhibition ELISA assay, a sandwich ELISA assay, an ELISA microarray, an amplified luminescent proximity homogenous assay-linked immunosorbent assay, a bioluminescence assay, a fluorescence resonance energy transfer (FRET) immunoassay, a lateral flow immunoassay, or combinations thereof.

7. The method of claim 5, wherein the immunoassay comprises HAPLN1 polyclonal antibodies, HAPLN1 monoclonal antibodies, or a combination thereof.

8. The method of claim 1, wherein the HAPLN1 protein comprises full-length HAPLN1, a HAPLN1 matrikine, a functional HAPLN1 domain or variant thereof, or combinations thereof.

9. The method of claim 1, wherein the HAPLN1 protein comprises an amino acid sequence having at least 95% identity to any one of SEQ ID NOs: 1-13.

10. The method of claim 1, wherein the first multiple myeloma prognosis for the subject comprises a reduced progression-free survival.

11. The method of claim 1, wherein the method is repeated one or more times.

12. The method of claim 1, wherein a bone marrow sample is collected from the subject prior to collecting the peripheral blood sample from the subject.

13. The method of claim 12, further comprising detecting a level of HAPLN1 protein in the bone marrow sample and comparing the level of the HAPLN1 protein in the bone marrow sample to the level of the HAPLN1 protein in the peripheral blood sample.

14. The method of claim 1, wherein the second multiple myeloma prognosis for the subject comprises drug resistance to a standard multiple myeloma treatment, the standard multiple myeloma treatment comprising bortezomib, lenalidomide, dexamethasone, an anti-CD38 antibody, autologous stem cell transplantation, or combinations thereof.Atty Docket Nos. P250229W001 | 218707-0027-W00115. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of a non-standard multiple myeloma treatment.

16. The method of claim 15, wherein the non-standard multiple myeloma treatment comprises carfilzomib, selinexor, chimeric antigen receptor (CAR) T-cell therapy, pomalidomide, or combinations thereof.

17. A method of determining treatment for a subject having multiple myeloma, the method comprising:collecting a peripheral blood sample from the subject;detecting a level of HAPLN1 protein in the peripheral blood sample;comparing the level of the HAPLN1 protein in the peripheral blood sample to a baseline level of HAPLN1 protein in a control sample; anddetermining an appropriate multiple myeloma treatment for the subject based on the level of the HAPLN1 protein in the peripheral blood sample relative to the baseline level of HAPLN1 protein in the control sample;wherein when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a non-standard multiple myeloma treatment; or wherein when the level of HAPLN1 protein in the peripheral blood sample is not greater than the baseline level of HAPLN1 protein in the control sample, the subject is administered a therapeutically effective amount of a standard multiple myeloma treatment.

18. The method of claim 17, wherein the non-standard multiple myeloma treatment comprises carfilzomib, selinexor, chimeric antigen receptor (CAR) T-cell therapy, pomalidomide, or combinations thereof.

19. The method of claim 17, wherein the standard multiple myeloma treatment comprises bortezomib, lenalidomide, dexamethasone, an anti-CD38 antibody, autologous stem cell transplantation, or combinations thereof.Atty Docket Nos. P250229W001 | 218707-0027-W00120. The method of claim 17, wherein when the level of HAPLN1 protein in the peripheral blood sample is greater than the baseline level of HAPLN1 protein in the control sample, the subject has drug resistance to the standard multiple myeloma treatment.

21. The method of claim 17, further comprising administering to the subject a therapeutically effective amount of an additional multiple myeloma treatment, the additional multiple myeloma treatment comprising a proteasome inhibitor, a nuclear export inhibitor, a steroid, an immunomodulatory drug, a DNA damaging agent, a chemotherapy, an antibody, radiation, a BCL-2 inhibitor, CAR T-cell therapy, autologous stem cell transplantation, or combinations thereof.